SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Relay Therapeutics Reports Third-Quarter 2026 Results and Corporate Updates

The company said enrollment in its Phase 3 ReDiscover-2 trial is expected to finish in mid-year. Updated data from its ReInspire trial is slated for presentation at the 68th ASH Annual Meeting.

RLAY

Related stories